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The spreading of tumor cells to secondary sites (tumor metastasis) is a complex process
that involves multiple, sequential steps. Vascular adhesion and extravasation of circulat-
ing tumor cells (CTCs) is one, critical step. Curcumin, a natural compound extracted
from Curcuma longa, is known to have anti-tumoral, anti-proliferative, anti-inﬂammatory
properties and affect the expression of cell adhesion molecules, mostly by targeting the
NF-κB transcription factor. Here, upon treatment with curcumin, the vascular behavior of
three different estrogen receptor negative (ER−) breast adenocarcinoma cell lines (SK-BR-
3, MDA-MB-231, MDA-MB-468) is analyzed using a microﬂuidic system. First, the dose
response to curcumin is characterized at 24, 48, and 72 h using a XTT assay. For all three
cell lines, an IC50 larger than 20 μM is observed at 72 h; whereas no signiﬁcant reduction
in cell viability is detected for curcumin concentrations up to 10 μM. Upon 24 h treat-
ment at 10 μM of curcumin, SK-BR3 and MDA-MB-231 cells show a decrease in adhesion
propensity of 40% (p = 0.02) and 47% (p = 0.001), respectively. No signiﬁcant change is
documented for the less metastatic MDA-MB-468 cells. All three treated cell lines show a
20% increase in rolling velocity from 48.3 to 58.7 μm/s in SK-BR-3, from 64.1 to 73.77 μm/s
in MDA-MB-231, and from 57.5 to 74.4 μm/s in MDA-MB-468. Collectively, these results
suggest that mild curcumin treatments could limit the metastatic potential of these ade-
nocarcinoma cell lines, possibly by altering the expression of adhesion molecules, and
the organization and stiffness of the cell cytoskeleton. Future studies will elucidate the
biophysical mechanisms regulating this curcumin-induced behavior and further explore the
clinical relevance of these ﬁndings.
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INTRODUCTION
The spreading of primary tumors to secondary sites (tumor metas-
tasis) is responsible for a dramatic decrease in survival rate, with
about 90% of the deaths in cancer patients being related to metas-
tasis (Wittekind and Neid, 2005). Although, for a long time, this
has been considered as a late stage process in tumor growth,
recently it has been realized that metastatic niches can form and
progress almost simultaneously with the primary mass (Klein,
2009). Metastasis is a multi-step process where tumor cells have
to overcome several barriers before growing at secondary sites: (i)
invade the normal tissue surrounding the tumor mass; (ii) enter
the bloodstream; (iii) survive in the circulatory system; (iv) leave
the blood stream and inﬁltrate the normal tissue; and (v) prolifer-
ate there, evading the immune system surveillance (Morris et al.,
1997; Fidler, 2003; Chaffer and Weinberg, 2011). Each of these
steps represents an impediment to the distant spreading of the
disease that only a few primary tumor cells (one CTC out of a
billion of blood cells) can overcome. Yet, metastasis occurs very
often in cancer patients (Wong et al., 2001; Chambers et al., 2002).
A critical step in this process is the vascular transport of
tumor cells in the hostile hemodynamic environment and the
extravasation to secondary sites (Wyckoff et al., 2000). Circulating
tumor cells (CTCs), transported by the blood ﬂow, are subjected
to mechanical stress, generated by high shear forces and collisions
with other cells; and immunological stress, as these cells can be
recognized and attacked by lymphocytes (Al-Mehdi et al., 2000;
Chang et al., 2008; Vivier et al., 2008). Extravasation and inﬁltra-
tion are generally associated with pro-metastasis modiﬁcations of
the CTCs (i.e., epithelial–mesenchymal transition) that originate
in the primarymass and continue in the circulation (Iwatsuki et al.,
2010; Labelle et al., 2011). The actual mechanism for extravasation
depends on the tumor type and metastatic environment and can
involve the (i) geometrical trapping of CTCs in narrow blood
vessels (diameter <40 μm); (ii) adhesion to endothelial cells, in
a leukocyte-like fashion, mediated or not mediated by platelets;
and (iii) a combination of these mechanisms (Ribatti et al., 2006;
Miles et al., 2008).
In this study, the main focus is on the vascular adhesion
of CTCs under ﬂow, as schematically shown in Figure 1. This
process consists of two sequential steps: (i) CTC rolling over
the vascular walls, regulated by the engagement of endothelial
E-selectin and P-selectin with tumor cell glycoprotein such as
CD44, CEA, CD24, sulfate glycosaminoglycans (CS-GAGs), sia-
lylated glycosphingolipids; (ii) CTC ﬁrm arrest, regulated by other
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FIGURE 1 | Schematic representation of circulating tumor cells (CTCs in green) transported by the blood flow and tethering the endothelial cells
(blue) through ligand molecules.
endothelial receptors (ICAM-1, VCAM-1), and different families
of integrin molecules (αvβ3, β2 integrins; Wirtz et al., 2011; Geng
et al., 2012). In organs with high occurrence of metastasis, such as
the liver, this picture is even more complicated in that the char-
acteristic discontinuous and fenestrated endothelium leaves the
underlying extracellular matrix directly accessible to CTCs. More-
over, vascular adhesion is also supported by the reorganization
and deformation under ﬂow of the cell cytoskeleton. Although
tumor cells do not exhibit a leukocyte-like cortical cytoskeleton
which is capable of extensive and rapid deformation, it is pos-
sible that CTCs exposed to shear stresses in the circulation could
undergo transformations facilitating attachment to the vessel walls
(Davies et al., 2005). Indeed, ﬁrmarrest is a necessary condition for
the subsequent extravasation and colonization of the surrounding
tissue.
The development of therapeutic agents against metastatic dis-
ease is still in its infancy, due to a lack in understanding the leading
pathways and, most importantly, their alterations in secondary
tumor cells. Also, most of the efforts have been traditionally
oriented to eradicate tumor cells already proliferating at the sec-
ondary sites, neglecting theopportunity of blockingormodulating
one or multiple steps in the metastatic cascade (Chambers et al.,
2000). Novel micro- and nanotechnologies detecting, capturing,
and characterizing CTCs are providing new and more accurate
information on the biomechanical properties of malignant cells
in the circulation. Microﬂuidic systems used as diagnostic tools
are demonstrating the signiﬁcant correlation between higher CTC
counts in blood and lower patient survival (Cristofanilli et al.,
2004; King et al., 2009; Han et al., 2010; Hughes and King, 2012).
It is then reasonable to speculate that novel therapies, possi-
bly nanoparticle-based, could open new avenues for an effective
treatment of metastatic diseases by eradicating, or dramatically
lowering, the number of CTCs.
In this work, the effect of curcumin on the rolling and adhe-
sionmechanics under ﬂow of three estrogen receptor (ER−) breast
adenocarcinoma cell lines, namely SK-BR-3, MDA-MB-231, and
MDA-MB-468, is analyzed. These cell lines were chosen for their
different metastatic potential. Curcumin is a natural multi-target
compound with anti-tumoral and anti-inﬂammatory properties
(Kumar et al., 1998; Ray et al., 2003; Kunnumakkara et al., 2008;
Binion et al., 2009; Yodkeeree et al., 2010). Their rolling veloc-
ity and adhesion propensity are measured experimentally upon
treatment with curcumin, using a parallel plate ﬂow chamber
system.
MATERIALS AND METHODS
MATERIALS AND CHEMICALS
SK-BR-3, MDA-MB-231, MDA-MB-468 breast adenocarcinoma
cells were obtained from the American Type Cell Culture Collec-
tion (ATCC) and cultured in the recommendedmedium. SK-BR-3
were grown at 37◦C, under a humidiﬁed 5% CO2 and 95% air at
one atmosphere, MDA-MB-231 and MDA-MB-468 were grown
at 37◦C in a free gas exchange with atmospheric air. Collagen
type I from calf skin was obtained from Sigma Aldrich (St. Louis,
MO, USA). Curcumin (diferuloylmethane) and dimethyl sulfox-
ide (DMSO) were obtained from Fisher Scientiﬁc. XTT kit was
obtained from Trevigen (Gaithersburg, Maryland).
CYTOTOXIC EFFECT OF CURCUMIN AND XTT ASSAYS
Curcumin was ﬁrst dissolved in DMSO as a 10 mM stock solu-
tion and subsequently diluted in cell culture medium. Medium
containing the same amount of DMSOwas used as control at con-
centrations not exceeding the 0.1% v/v of the culture medium.
Cells were incubated with curcumin at 1, 10, 20, and 40 μM, at
three time points namely 24, 48, and 72 h. Cell proliferation was
measured with conventional XTT reduction assays. Brieﬂy, SK-
BR-3, MDA-MB-231, and MDA-MB-468 cells were inoculated at
a density of 5 × 103 cells in 96-well plates for 24 h in 200 μl of rec-
ommended medium. The culture supernatant was then removed
and medium containing the above mentioned curcumin concen-
trations was added to cells, subsequently incubated for 24, 48, and
72 h. After that, XTT-dye was mixed with phenol-free medium
and added to the samples. The plate was incubated for at least
1 h before reading. The absorbance of XTT-formazan dye was
then measured using a microplate reader at 490 nm. Twenty-ﬁve
repetitionswere performed for each time point and concentration.
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PARALLEL PLATE FLOW CHAMBER FOR CELL ROLLING AND ADHESION
Before ﬂow adhesion experiments, cells were ﬁrst incubated with
medium containing no FBS for 7 h and then treated with or with-
out curcumin at 10μM for 24 h. Subsequently, cells were detached
from culture dishes by mild trypsinization (0.25% trypsin/EDTA)
for 2min at 37◦C and incubated at 37◦C for 1 h to allow the regen-
eration of surface glycoproteins. After that, cells were washed in
PBS and resuspended at 106 cells/ml in serum-free medium con-
taining 0.1% bovine serum albumin, following standard protocols
(McCarty et al., 2000).
The rolling and adhesion behavior of the tumor cells, was
studied using a parallel plate ﬂow chamber system (Chen et al.,
1997; Brown and Larson, 2001; GlycoTechCorporation; Figure 2).
The system comprises a commercially available ﬂow chamber, a
syringe pump (Harvard Apparatus, MA), an inverted epiﬂuo-
rescent microscope (Nikon Ti-Eclipse) and a desktop computer
for data storage and analysis. The main constituents of the ﬂow
chamber are a deck, a rubber gasket and a glass slide. The rubber
gasket deﬁnes the geometry of the ﬂow region (length l = 20 mm;
width b = 10 mm; height h = 0.254 mm). The coverslips (slide),
closing the bottom of the chamber, were covered with a uniform
collagen layer. In particular, autoclaved 35 mm coverslips were
covered by a collagen solution obtained diluting collagen type
I from calf skin (Sigma Aldrich) in PBS to reach a concentra-
tion of about 50 mg/cm2. After about 5 h at room temperature,
the cover slips were rinsed in PBS and left under the bio-hood
to dry. To perfuse the solution at a ﬁxed wall shear rate S, ﬂow
rate Q is ﬁnely controlled through the syringe pump given that
S = 6Q/bh2.
After assembling all the components, the system was placed on
the stage of an epiﬂuorescent microscope (Nikon Ti-Eclipse). The
Andor’s Luca EM S camera utilizes a 658 × 496 “interline frame
transfer” EMCCD sensor to acquire the region of interest (ROI)
and allows for real time monitoring. For each experiment 106/ml
cells were perfused in 1 ml of serum-free medium, at a wall shear
rate of S = 10 s−1 (mimicking the circulation environment of
microvascular tumor vessels). Eight experiments were performed
for the SK-BR-3 and MDA-MB-468-treated and untreated cells,
and 10 experiments for the MDA-MB-231. All the experiments
lasted 12 min each.
Through ofﬂine data analysis on the movies derived from each
experiment, the number of ﬁrmly adhering cells on the substrate
and their mean rolling velocity were quantiﬁed. Firmly adhering
cells were those cells staying within the region of interest (10×
objective, ROI = 658 × 496 pixel) till the end of the experiment.
This number was normalized by the total number of injected cells
and the area of the ROI (∼0.33 × 10−6 m2) deriving the adhesion
propensity. The rolling velocity was calculated as the displace-
ment of the centroid of the cells divided by the time interval of
their observation (on average about 10 s). The rolling velocity
was calculated for 12 cells in three different SK-BR-3 experiments
(n = 36), and six cells in eight different MDA-MB-231 and MDA-
MB-468 experiments (n= 48), for both the treated and the control
group.
STATISTICAL ANALYSIS
Data are expressed as means ± SD. Statistical signiﬁcance of dif-
ferences between means was determined by one-way ANOVA.
Probability values of p < 0.05 were considered statistically
signiﬁcant.
RESULTS AND DISCUSSION
The cytotoxic effect of curcumin on SK-BR-3,MDA-MB-231, and
MDA-MB-468 cells was analyzed using a XTT proliferation assay.
Cells were incubated with curcumin at different doses, namely
1, 10, 20, and 40 μM, and for three time points, namely 24, 48,
FIGURE 2 |The parallel plate flow chamber system composed of the
microfluidic chamber (deck, gasket, and microscope slide represented in
the oval at left); the syringe pump, the epifluorescent microscope and a
desktop computer.
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and 72 h. The cell viability was measured following the proto-
cols described in Section “Materials andMethods” and is reported
in the bar charts of Figure 3, for 25 repetitions in each cell line.
As expected the percentage of viable cells reduces as the concen-
tration and the duration of the treatment increase. Interestingly,
for concentrations lower and equal to 10 μM, curcumin has
no signiﬁcant effect on the cell viability. Note that for the con-
trol experiments, cell culture medium was added with the same
amount of DMSO used in the actual experiments for dissolving
curcumin. This volume was about 0.1% of the total medium vol-
ume and no sign of toxicity was observed on the cells. For larger
concentrations, 20 and 40 μM, the curcumin treatment limits cell
proliferation in a dose and time dependentmanner. Cell viabilities
lower than 50% can only be observed at the highest concentra-
tion and longer time points (48 and 72 h). The IC50 is reached
at ∼20 μM for the SK-BR-3 and MDA-MB-468 at 72 h; and at
∼40 μM for the MDA-MB-231 at 72 h. This is in agreement
with most literature on curcumin (Aoki et al., 2007). From this
assay, the exposure to 10 μM of curcumin for 24 h was consid-
ered amild treatment inducing no signiﬁcant, direct effects on cell
viability.
The effect of curcumin on the rolling and adhesion behavior of
the three breast adenocarcinoma cells lines SK-BR-3, MDA-MB-
231, and MDA-MB-468 was analyzed using a parallel plate ﬂow
chamber, traditionally employed for the analysis of leucocyte adhe-
sion and rolling (Lawrence et al., 1987). The cells,mildly pretreated
with curcumin (24 h at 10 μM) as detailed in Section “Materials
and Methods,” were infused in the apparatus depicted in Figure 2
and their rolling velocity and ﬁrm adhesion was quantiﬁed via
post processing of the images taken with an epiﬂuorescent micro-
scope. The bar charts of Figure 4 present the results of the ﬂow
chamber assay. Figure 4A shows the adhesion propensity of the
curcumin-treated cells (Curc-treated) and untreated cells (Ctr), as
the ratio between the absolute number of adhering cells (nadh),
the total number of injected cells (ninj = 106), and the area of the
region of interest (A = 0.33× 10−6 m2). SK-BR-3,MDA-MB-231,
andMDA-MB-468-treated cells present an adhesion propensity of
90.7 ± 29.2, 58.58 ± 19.70, and 132.97 ± 31.34#/m2, respectively.
This means that for a vessel of 50 μm in diameter with a 500 μm
length (vascular area ∼1 mm2), about 300 SK-BR-3, 180 MDA-
MB-231, and 400 MDA-MB-468 cells would ﬁrmly adhere under
the same biophysical conditions and assuming that 106 CTCs enter
the speciﬁc vessel. On the other hand, the untreated cells exhibit a
larger adhesion propensity of 151.1 ± 60.84, 109.69 ± 38.19, and
155.42 ± 20.74#/m2, for the SK-BR-3, MDA-MB-231, and MDA-
MB-468, respectively. The difference between the two populations
(Curc-treated and Ctr) is signiﬁcant for the SK-BR-3 and even
more for the highly metastatic MDA-MB-231 cells. More specif-
ically, the curcumin-treated SK-BR-3 cells show a 40% decrease
(p = 0.02) in adhesion and the curcumin-treated MDA-MD-
231 a 47% decrease (p = 0.001) as compared to the control
group. Conversely, the difference in adhesion propensity between
curcumin-treatedMDA-MB-468 cells and the control group is not
statistically signiﬁcant (p = 0.099).
Rolling velocity is reported in Figure 4B. This physical quan-
tity was estimated as the ratio between the displacement of the
cell centroid over the corresponding observation time. Despite the
large standard deviation, this analysis shows that there is a signiﬁ-
cant difference between the two groups (Curc-treated and Ctr) in
all three cell lines: SK-BR-3 andMDA-MB-231-treated tumor cells
roll ∼1.2 times faster than the control cells (p = 0.01, p = 0.009,
respectively), MDA-MB-468-treated tumor cells rolls ∼1.3 times
faster than the control cells (p = 0.00005). In particular, the rolling
velocities are 58.66 ± 20.29 and 48.33 ± 11.3 μm/s for SK-BR-
3-treated and untreated cells, 73.77 ± 21.21 and 64.1 ± 12.89
for MDA-MB-231-treated and untreated cells, 74.38 ± 24.88
and 57.49 ± 11.96 for MDA-MB-468-treated and untreated cells,
respectively. Indeed, the higher rolling velocity correlates well with
the lower adhesion propensity observed above.
These preliminary results collectively would suggest that mild
treatments with curcumin could impair cell adhesion and increase
cell rolling under ﬂow over normal, untreated cells. Indeed, this
could reduce the metastatic potential of CTCs. Understanding
the mechanisms regulating the observed alteration in the behav-
ior of SK-BR-3, MDA-MB-231, and MDA-MB-468 cells is out of
the scope of this preliminary study. However, it has already been
reported that curcumin treatments alter theorganizationofmicro-
ﬁlaments and increase the overall quantity of F-actin. This would
affect cell motility and deformability, which are crucial elements
in supporting tumor cell circulation and survival in the blood
stream.Moreover, recently it has been shown that CTCs reattach in
distant tissues by amechanism that is tubulin-dependent and sup-
pressed by polymerized actin (Holy, 2004; Matrone et al., 2010).
In addition, curcumin is known to decrease the expression and
FIGURE 3 | Proliferation of (A) SK-BR-3, (B) MDA-MB-231, (C) MDA-MB-
468 cells exposed to different concentrations of curcumin (1, 10, 20, and
40 μM) at three time points (24, 48, and 72 h). Note that cell proliferation is
not affected at curcumin concentrations below 10 μM up to 72 h (n = 25). The
asterisk symbol “*” denotes signiﬁcant difference (p < 0.05) as compared to
control (Ctr).
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FIGURE 4 | (A) Adhesion and (B) rolling behavior of SK-BR-3 (white),
MDA-MB-231(gray), MDA-MB-468 (blue) cells treated with curcumin
(Curc-treated) at 10 μM for 24 h, and not treated cells (Ctr). The number of
ﬁrmly adhering cells (nadh) is normalized by the total number of injected cells
(ninj = 106) and the area of the region of interest (A = 0.33 × 10−6 m2). Data
are plotted as mean ± SD. The asterisk symbol “*” denotes signiﬁcant
difference (p < 0.05) as compared to control (Ctr). (C) Image of ﬁrmly
adhering SK-BR3 cells on the substrate at the end of the experiment. (D)
Captured frames showing the displacement of a rolling cell on the
substrate.
modulate the activity of membrane adhesion molecules by act-
ing on the transcription factor NF-κB. For instance, the curcumin
inhibition of NF-κB completely blocked TNF-α induced expres-
sion of adhesion molecules (ICAM-1, VCAM-1, and E-selectin)
on HUVECs and human intestinal microvascular endothelial cells
attenuating leucocytes adhesion (Kumar et al., 1998; Ray et al.,
2003; Binion et al., 2009). Therefore, in the present case, it is rea-
sonable to speculate that curcumin effects could depend, at least
in part, on a reduced expression or more likely, on the modulation
of integrins receptor activity (mostly α1β1 and α2β1) thus limit-
ing the adhesion propensity under ﬂow (Park et al., 2006; Ivascu
and Kubbies, 2007). Here, it is important to note that integrins,
expressed on cellular membrane, can speciﬁcally bind to the col-
lagen type I, deposited on the ﬂow chamber glass slide. Also, in
organs with high metastatic occurrence, such as the liver, the dis-
continuous, fenestrated endothelium allows the CTCs to directly
interact and bind to ECM components. For this reason, colla-
gen type I, has been also used in ﬂow chamber experiments to
assess the adhesive behavior of cells and CTCs (Haier et al., 1999;
Wendel et al., 2012).
Finally, curcumin, a natural compound extracted from Cur-
cuma longa, has been demonstrated to have a wide spectrum
of biological and pharmacological activities. In particular, it
exhibits antiviral, antibacterial, antioxidant, anti-inﬂammatory,
anti-proliferative, and anti-angiogenic properties (Aggarwal et al.,
2003; Holt et al., 2005). Animal and human studies have sug-
gested its potential use in the treatment of inﬂammation and
cancer, mostly because of its potent effect on the NF-κB path-
way (Kawamori et al., 1999; Aggarwal, 2004). However, the major
drawback in its clinical use is the very low bioavailability and
biodistribution, mostly due to its poor absorption from the gut,
rapid metabolism and elimination (Shoba et al., 1998; Anand
et al., 2007). The formulation of curcumin into nanoparticles
could avoid the drawbacks listed above and enhance its curative
properties.
CONCLUSION
The ER negative breast metastatic cells, SK-BR-3, MDA-MB-
231, and MDA-MB-468, cells were treated with curcumin, at
three different time points. For sufﬁciently large curcumin doses
(≥20 μM), signiﬁcant cell death is induced at 72 h. Conversely, a
mild treatment with curcumin (≤10 μM at 24 h), did not show
any signiﬁcant change in cell viability but did affect the vascu-
lar behavior of the cells. This was demonstrated by assessing the
cell adhesion and rolling velocity in a parallel plate ﬂow chamber
system. The SK-BR-3 cells showed a 40% decrease (p = 0.02) in
cell adhesion propensity and 20% increase (p = 0.001) in rolling
velocity. The MDA-MB-231-treated cells showed almost a 50%
decrease (p = 0.001) in cell adhesion propensity and about 15%
increase (p = 0.009) in rolling velocity. TheMDA-MB-468-treated
cells did not show any statistically signiﬁcant decrease in adhesion
propensity, but did roll 1.3 times faster than the control group
(p = 0.00005).
Collectively, these results suggest that mild curcumin treat-
ments of CTCs could lower or even prevent the occurrence of
metastasis, by reducing CTCs adhesion at secondary vascular
sites. Future works will have to elucidate the mechanisms reg-
ulating the observed alteration in tumor cell behavior and the
speciﬁc pathways involved in each cell line studied, by charac-
terizing the expression and activity of cell membrane receptors,
the organization of the cell cytoskeleton and its deformability.
However, the proper delivery of sufﬁcient doses of curcumin
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to CTCs could provide a new strategy to prevent the metastatic
spread.
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